Merck & Co., Inc. (NYSE:MRK) is another biopharmaceutical company on the list of the 10 undervalued blue chip stocks analysts ...

Dr. Deano Reyes, an LGBTQ+ health doctor and the medical director of Hara Clinic, and Ico Johnson, the vice president of HIV ...

Biological E partners with China’s Recbio to produce REC603 a 9-valent HPV vaccine in India The collaboration aims to expand ...

China's newly approved and domestically developed 9-valent human papillomavirus vaccine is expected to give potential recipients more access to the cancer-preventing shot. This makes China the second ...

On May 23, 2025, Merck affirmed its position regarding the current dosing regimens for GARDASIL 9. The company stated that the CDC recommendation should remain consistent with the approved product ...

Gardasil/Gardasil 9 sales declined 41% to $1.33 billion in the first quarter of 2025, primarily due to lower demand in China, partially offset by higher demand in most international regions ...

Until now, only US pharmaceutical company Merck & Co, known as MSD outside the US and Canada, manufactured the 9-valent version, sold under the brand name Gardasil 9.

Keytruda was last year’s top-selling drug with sales of $29.482 billion, while Gardasil/Gardasil 9 racked up $8.583 billion.

Gardasil/Gardasil 9 shot up 59% to $1.5 billion on a bounce back in demand as COVID-19 restrictions eased and strong uptake in China.